ID: h-78a93db210
Hypothesis
Direct ISR target engagement likely requires trazodone doses around 150-200 mg/day for disease-modifying effects in dementia
The most credible disease-modifying model is that trazodone must reach a higher exposure range, likely around 150-200 mg/day, to engage the PERK-eIF2alpha integrated stress response in neurons and restore translation.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 3 oppose
🧪 Overview
The most credible disease-modifying model is that trazodone must reach a higher exposure range, likely around 150-200 mg/day, to engage the PERK-eIF2alpha integrated stress response in neurons and restore translation. This remains a mechanistically grounded but unvalidated human threshold derived mainly from preclinical tauopathy/prion data and supported by the observation that many real-world dementia prescriptions were likely below this range.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Target Gene: EIF2AK3 EIF2S1 ATF4 DDIT3"]
B["Molecular Mechanism<br/>Pathway Activation"]
C["Cellular Phenotype<br/>Neuronal / Glial Response"]
D["Network Effect<br/>Circuit-Level Consequence"]
E["Disease Relevance<br/>Neurodegeneration Link"]
A --> B --> C --> D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix4 supports3 contradicts
Supports
Trazodone rescued neurodegeneration and reversed eIF2alpha-P-linked translational repression in mouse prion and tauopathy models, with authors mapping efficacious exposure to a clinically relevant human dose estimate.
Supports
Follow-up proteomics showed trazodone rescued synaptic and mitochondrial nascent proteomes downstream of ISR dysregulation.
Supports
AD brains show activated UPR/ISR biology, supporting target relevance in human disease.
Supports
Phosphorylated eIF2alpha colocalizes with degenerating tau-positive neurons in AD.
Contradicts
The proposed ~194 mg/day threshold is a mouse-to-human extrapolation, not a demonstrated human CNS target-engagement threshold.
Contradicts
Human clinical pharmacology at common doses is dominated by receptor occupancy and sedative effects, making mechanistic attribution uncertain.
Contradicts
Naturalistic dementia cohort data do not establish disease modification at any dose and were heavily confounded by low exposure and indication bias.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — EIF2AK3;
No curated PDB or AlphaFold mapping for EIF2AK3; yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for EIF2AK3; EIF2S1; ATF4; DDIT3 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for EIF2AK3; EIF2S1; ATF4; DDIT3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0813
Events (7d)
1
Price History
▼2.6%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF patients with Alzheimer's disease are randomized to receive trazodone 150–200 mg/day for 12 weeks THEN a measurable reduction in cerebrospinal fluid phosphorylated eIF2α (p‑eIF2α) levels will be ob | CSF p‑eIF2α concentration decreases by ≥20 % (or falls below the assay’s lower limit of quantification) in the high‑dose group relative to the low‑dose group af | — no observation — | pending | 0.55 |
| IF individuals with prodromal or mild dementia are treated with trazodone 150–200 mg/day for 12 months THEN their annual decline in global cognition (as measured by change in MMSE score) will be at le | High‑dose trazodone group shows an average MMSE decline of ≤2 points over 12 months, whereas the low‑dose group declines ≥4 points. | — no observation — | pending | 0.50 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF patients with Alzheimer's disease are randomized to receive trazodone 150–200 mg/day for 12 weeks THEN a measurable reduction in cerebrospinal fluid phosphorylated eIF2α (p‑eIF2α) levels will be observed compared to those receiving <100 mg/day.
Predicted outcome: CSF p‑eIF2α concentration decreases by ≥20 % (or falls below the assay’s lower limit of quantification) in the high‑dose group relative to the low‑dos
Falsification: No statistically significant difference in CSF p‑eIF2α levels between the high‑dose and low‑dose groups after 12 weeks (p > 0.05).
pendingconf 50%
IF individuals with prodromal or mild dementia are treated with trazodone 150–200 mg/day for 12 months THEN their annual decline in global cognition (as measured by change in MMSE score) will be at least 2 points less than that of matched patients receiving <100 mg/day.
Predicted outcome: High‑dose trazodone group shows an average MMSE decline of ≤2 points over 12 months, whereas the low‑dose group declines ≥4 points.
Falsification: The high‑dose group exhibits an MMSE decline equal to or greater than the low‑dose group (no protective effect), indicating no dose‑dependent disease‑modifying benefit.
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.